
Annual report 2024
added 03-21-2026
Aptorum Group Limited EPS Ratio 2011-2026 | APM
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.78 | -0.62 | -2.75 | -7.15 | 0.2 | -0.64 | -0.53 | -0.09 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.2 | -7.15 | -1.55 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Verastem
VSTM
|
-3.02 | $ 5.04 | -4.73 % | $ 349 M | ||
|
VistaGen Therapeutics
VTGN
|
-1.67 | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-1.96 | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-0.39 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Xenon Pharmaceuticals
XENE
|
-3.01 | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
ChemoCentryx
CCXI
|
-1.89 | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
-1.08 | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Summit Therapeutics
SMMT
|
-1.44 | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-0.17 | $ 4.29 | -3.6 % | $ 822 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
Fusion Pharmaceuticals
FUSN
|
-1.45 | - | - | $ 1.41 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 19.01 | -2.66 % | $ 889 M | ||
|
Gritstone Oncology
GRTS
|
-1.2 | - | 0.42 % | $ 213 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 20.75 | -3.35 % | $ 3.44 B | ||
|
Aligos Therapeutics
ALGS
|
-2.45 | $ 6.66 | -5.4 % | $ 65.8 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Alkermes plc
ALKS
|
1.47 | $ 29.39 | -1.77 % | $ 4.84 B | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 2.68 | -4.96 % | $ 269 M | ||
|
AbbVie
ABBV
|
1.02 | $ 209.4 | -0.81 % | $ 370 B | ||
|
AbCellera Biologics
ABCL
|
-0.49 | $ 3.27 | -2.39 % | $ 977 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M |